Literature DB >> 21122639

Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing.

Katherine R Gerrald1, Dave L Dixon, Debra J Barnette, Virginia G Williams.   

Abstract

BACKGROUND: Hyperlipidemia is a significant, modifiable risk factor for developing coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) goal achievement has improved overall, but many high-risk patients remain above the desired LDL-C goals. Published data have demonstrated the ability of pharmacist-managed lipid clinics to improve lipid management in a variety of clinical settings.
OBJECTIVE: This observational analysis aimed to report the impact of a newly developed hospital-based, outpatient lipid clinic by the use of point-of-care testing on LDL-C goal attainment.
METHODS: A retrospective, observational analysis was conducted from February 2007 to December 2008. The primary outcome measure was the change in the proportion of patients who achieved their LDL-C goal at the end of the observation period compared with baseline.
RESULTS: A total of 81 patients met study inclusion criteria. Mean duration of follow-up was 9.0 ± 4.9 (SD) months. At the end of the observation period, 82.9% of patients achieved their LDL-C goal compared with 55.3% at baseline (P < .0001). The mean LDL-C decreased from 103 ± 45 mg/dL at baseline to 82 ± 28 mg/dL at the end of the observation period (P < .0001).
CONCLUSION: An outpatient hospital-based, pharmacist-managed lipid clinic improved LDL-C goal attainment. Our results are unique in that pharmacists used point-of-care testing to obtain lipid results for making therapy adjustments during the face-to-face visit.
Copyright © 2010 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122639     DOI: 10.1016/j.jacl.2010.02.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  7 in total

Review 1.  Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?

Authors:  Ines Krass; Adrian T Walker; Gerald F Watts
Journal:  Int J Clin Pharm       Date:  2012-05-24

2.  Proposal for a pharmacogenetics certificate program for pharmacists.

Authors:  Susanne B Haga; Jivan Moaddeb
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

3.  Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.

Authors:  Susanne B Haga; Nancy M Allen LaPointe; Alex Cho; Shelby D Reed; Rachel Mills; Jivan Moaddeb; Geoffrey S Ginsburg
Journal:  Pharmacogenomics       Date:  2014-09       Impact factor: 2.533

4.  The detection of influenza virus at the community pharmacy to improve the management of local residents with influenza or influenza-like disease.

Authors:  Akio Kawachi; Yusuke Sakamoto; Shunya Mouri; Mitsuaki Fukumori; Riku Kawano; Takaya Murakami; Junichiro Sonoda; Keiko Narumi; Yoshihiro Shimodozono; Kenji Etoh; Susumu Chiyotanda; Takashi Furuie; Keizo Sato; Masao Fukumori; Toshiro Motoya
Journal:  J Pharm Health Care Sci       Date:  2017-08-08

5.  Point-of-care testing to promote cardiovascular disease risk assessment: A proof of concept study.

Authors:  Kunal N Karmali; Tiffany Brown; Thomas Sanchez; Timothy Long; Stephen D Persell
Journal:  Prev Med Rep       Date:  2017-06-15

6.  The potential role of clinical pharmacy services in patients with cardiovascular diseases.

Authors:  Azita Hajhossein Talasaz
Journal:  J Tehran Heart Cent       Date:  2012-05-31

7.  Impact of point-of-care tests in community pharmacies: a systematic review and meta-analysis.

Authors:  Ali Albasri; Ann Van den Bruel; Gail Hayward; Richard J McManus; James Peter Sheppard; Jan Yvan Jos Verbakel
Journal:  BMJ Open       Date:  2020-05-15       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.